Editas Medicine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

Gilmore O’Neill

CEOGilmore O’Neill

Employees

246

Employees246

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2013

Founded2013

Employees

246

Employees246

EDIT Key Statistics

Market cap

250.88M

Market cap250.88M

Price-Earnings ratio

-0.98

Price-Earnings ratio-0.98

Dividend yield

—

Dividend yield—

Average volume

1.19M

Average volume1.19M

High today

$2.84

High today$2.84

Low today

$2.72

Low today$2.72

Open price

$2.77

Open price$2.77

Volume

1.49M

Volume1.49M

52 Week high

$4.12

52 Week high$4.12

52 Week low

$0.9101

52 Week low$0.9101

EDIT News

Simply Wall St 19m

Editas Medicine, Inc. Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Editas Medicine, Inc. ( ) shares have been powering on, with a gain of 26% in the last thirty days. Not all shareholders will be...

TipRanks 6d

Editas Medicine price target raised to $4 from $3 at Wells Fargo

Wells Fargo raised the firm’s price target on Editas Medicine (EDIT) to $4 from $3 and keeps an Equal Weight rating on the shares. The firm thinks the LDLR upre...

Analyst ratings

43%

of 14 ratings

Buy

42.9%

Hold

42.9%

Sell

14.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics